These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
692 related articles for article (PubMed ID: 27977392)
21. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508 [TBL] [Abstract][Full Text] [Related]
22. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Lacourcière Y; Neutel JM; Schumacher H Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450 [TBL] [Abstract][Full Text] [Related]
23. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Scheen AJ Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129 [TBL] [Abstract][Full Text] [Related]
24. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). Tytus RH; Burgess ED; Assouline L; Vanjaka A Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822 [TBL] [Abstract][Full Text] [Related]
25. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH). Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD; Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460 [TBL] [Abstract][Full Text] [Related]
26. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Shimada K; Ogihara T; Saruta T; Kuramoto K; Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495 [TBL] [Abstract][Full Text] [Related]
27. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Weiss RJ; Stapff M; Lin Y Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484 [TBL] [Abstract][Full Text] [Related]
29. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Kengne AP; Czernichow S; Huxley R; Grobbee D; Woodward M; Neal B; Zoungas S; Cooper M; Glasziou P; Hamet P; Harrap SB; Mancia G; Poulter N; Williams B; Chalmers J; Hypertension; 2009 Aug; 54(2):399-404. PubMed ID: 19470869 [TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC Clin Ther; 2016 Oct; 38(10):2265-2276. PubMed ID: 27692976 [TBL] [Abstract][Full Text] [Related]
31. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534 [TBL] [Abstract][Full Text] [Related]
32. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC; Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566 [TBL] [Abstract][Full Text] [Related]
33. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367 [TBL] [Abstract][Full Text] [Related]
34. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Liu J; Pong A; Gallo S; Darekar A; Terra SG Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361 [TBL] [Abstract][Full Text] [Related]
35. Association of the optic disc structure with the use of antihypertensive medications: the thessaloniki eye study. Harris A; Topouzis F; Wilson MR; Founti P; Kheradiya NS; Anastasopoulos E; Gong G; Yu F; Jonescu-Cuypers CP; Pappas T; Koskosas A; Coleman AL J Glaucoma; 2013 Sep; 22(7):526-31. PubMed ID: 22411020 [TBL] [Abstract][Full Text] [Related]
36. [Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus]. Statsenko ME; Derevianchenko MV; Pastukhova OR Kardiologiia; 2014; 54(11):20-4. PubMed ID: 25902654 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. Okada K; Hoshide S; Kato M; Kanegae H; Ishibashi S; Kario K J Clin Hypertens (Greenwich); 2021 Apr; 23(4):860-869. PubMed ID: 33326172 [TBL] [Abstract][Full Text] [Related]
38. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884 [TBL] [Abstract][Full Text] [Related]
39. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006 [TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]